论文部分内容阅读
旨在探讨鸡腿菇复合制剂的抗肿瘤作用,为鸡腿菇复合制剂的推广应用提供理论基础。通过腹股沟皮下注射S180肿瘤细胞建立小鼠肿瘤模型,把接种肿瘤细胞后的小鼠随机分为阴性对照组,阳性对照组,鸡腿菇复合制剂低、中、高剂量组,2周后检测小鼠体重和肿瘤大小的不同。结果表明抗癌药物环磷酰胺的肿瘤抑制率为71.8%;鸡腿菇复合制剂低剂量组(1 233 mg·kg-1)、中剂量组(2 466 mg·kg-1)和高剂量组(3 699 mg·kg-1)的肿瘤抑制率分别为14.3%、43.5%和50.4%。这说明在实验条件下,鸡腿菇复合制剂具有明显抑瘤作用,并呈现一定的剂量依赖性。
The aim of this study was to investigate the antitumor effect of Coprinus comatus compound preparation and to provide a theoretical basis for the popularization and application of Coprinus comatus composite preparation. The mouse tumor model was established by subcutaneous injection of S180 tumor cells in the groin, and the mice inoculated with tumor cells were randomly divided into the negative control group, the positive control group, the Coprinus comatus compound preparation low, medium and high dose groups, and the mice were tested after 2 weeks Body weight and tumor size difference. The results showed that the anticancer drug cyclophosphamide tumor inhibition rate was 71.8%; Coprinus comatus low dose group (1 233 mg · kg-1), middle dose group (2 466 mg · kg-1) and high dose group 3 699 mg · kg-1) were 14.3%, 43.5% and 50.4%, respectively. This shows that under the experimental conditions, Coprinus comatus compound has obvious anti-tumor effect, and showed a certain dose-dependent.